DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
NEW YORK, Feb. 22, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased DaVita Inc. (NYSE:DVA) securities between August 5, 2015 and October 21, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/davita-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting.
On January 6, 2017, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis.
If you suffered a loss in DaVita you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/davita-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
